Publicacións nas que colabora con Andrzej Budaj (25)

2023

  1. Socioeconomic variations determine the clinical presentation, aetiology, and outcome of infective endocarditis: a prospective cohort study from the ESC-EORP EURO-ENDO (European Infective Endocarditis) registry

    European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 9, Núm. 1, pp. 85-96

2022

  1. A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction

    Circulation, Vol. 146, Núm. 16, pp. 1196-1206

  2. Characteristics, management, and outcomes of patients with left-sided infective endocarditis complicated by heart failure: a substudy of the ESC-EORP EURO-ENDO (European infective endocarditis) registry

    European Journal of Heart Failure, Vol. 24, Núm. 7, pp. 1253-1265

2021

  1. Contemporary Management of Severe Symptomatic Aortic Stenosis

    Journal of the American College of Cardiology, Vol. 78, Núm. 22, pp. 2131-2143

  2. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

    Journal of the American College of Cardiology, Vol. 78, Núm. 5, pp. 421-433

  3. The ESC-EORP Chronic Ischaemic Cardiovascular Disease Long Term (CICD LT) registry

    European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 7, Núm. 1, pp. 28-33

2020

  1. ESC core curriculum for the cardiologist

    European Heart Journal, Vol. 41, Núm. 38, pp. 3605-3692

2019

  1. Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: A prospective cohort study

    European Heart Journal, Vol. 40, Núm. 39, pp. 3222-3232B

  2. Dapagliflozin and cardiovascular outcomes in type 2 diabetes

    New England Journal of Medicine, Vol. 380, Núm. 4, pp. 347-357

  3. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

    The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 8, pp. 618-628

  4. Roadmap for cardiovascular education across the European Society of Cardiology: Inspiring better knowledge and skills, now and for the future

    European Heart Journal, Vol. 40, Núm. 21, pp. 1728-1738

2018

  1. Alirocumab and cardiovascular outcomes after acute coronary syndrome

    New England Journal of Medicine, Vol. 379, Núm. 22, pp. 2097-2107

2016

  1. Cardiovascular and other outcomes postintervention with insulin glargine and omega-3 fatty acids (ORIGINALE)

    Diabetes Care, Vol. 39, Núm. 5, pp. 709-716

2014

  1. Effect of darapladib on major coronary events after an acute coronary syndrome: The SOLID-TIMI 52 randomized clinical trial

    JAMA - Journal of the American Medical Association, Vol. 312, Núm. 10, pp. 1006-1015

  2. Erratum: Effect of darapladib on major coronary events after an acute coronary syndrome: The SOLID-TIMI 52 randomized clinical trial (JAMA (2014) 312:10(1006-1015))

    JAMA - Journal of the American Medical Association

2013

  1. 2013 ESC guidelines on the management of stable coronary artery disease

    European Heart Journal, Vol. 34, Núm. 38, pp. 2949-3003

  2. Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus

    JAMA Internal Medicine, Vol. 173, Núm. 18, pp. 1682-1692

2012

  1. Basal insulin and cardiovascular and other outcomes in dysglycemia

    New England Journal of Medicine, Vol. 367, Núm. 4, pp. 319-328

  2. N-3 fatty acids and cardiovascular outcomes in patients with dysglycemia

    New England Journal of Medicine, Vol. 367, Núm. 4, pp. 309-318

2008

  1. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention)

    American Heart Journal, Vol. 155, Núm. 1, pp. 26.e1-26.e13